阿瑞匹坦(Aprepitant) - 药物靶点：NK1R_在研适应症：术后恶心呕吐，化疗引起的恶心和呕吐，恶心_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Aprepitant (JAN/USP/INN)、HT-001、HTX-019

+ [14]

靶点

NK1R

作用机制

NK1R 拮抗剂(神经激肽-1-受体拮抗剂)

治疗领域

其他疾病感染皮肤和肌肉骨骼疾病

在研适应症

术后恶心呕吐化疗引起的恶心和呕吐恶心+ [5]

非在研适应症

急性髓性白血病晚期非小细胞肺癌乳腺癌+ [12]

原研机构

Merck Sharp & Dohme Corp.

在研机构

石药集团中诺药业（石家庄）有限公司

Ono Pharmaceutical Co., Ltd.

Merck Sharp & Dohme Corp.

+ [4]

非在研机构

Merck Sharp & Dohme LLCMerck Frosst Canada Ltd.Nuformix Technologies Ltd.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2003-03-26),

化疗引起的恶心和呕吐

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)

登录后查看时间轴

结构

分子式C23H21F7N4O3

InChIKeyATALOFNDEOCMKK-OITMNORJSA-N

CAS号170729-80-3

关联

296

项与阿瑞匹坦相关的临床试验

NCT06697782 / Not yet recruitingN/AIIT

Clinical Study of Aprepitant and Ondansetron Monotherapy or Combination in the Treatment of Postoperative Nausea and Vomiting in Thyroid Carcinoma

The vast majority of patients treated prophylactically with "first-line" antiemetics in the 5-hydroxytryptamine (5-HT3) receptor antagonist class still have significant PONV. Combination therapies with different pharmacologic bases have the potential to reduce the incidence of PONV. This study is a multicenter, three-arm, prospective study to evaluate the efficacy and safety of aprepitant and ondansetron, monotherapy or in combination, in the prevention of nausea and vomiting after surgery for thyroid cancer.

开始日期2024-12-01

申办/合作机构

郑州大学第一附属医院

NCT06543966 / Not yet recruiting临床3期

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection in the Prevention of Post-operative Nausea and Vomiting

A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,

开始日期2024-10-28

申办/合作机构

石药集团中诺药业（石家庄）有限公司

ChiCTR2400089511 / Suspended临床1期IIT

Efficacy and safety of Aprepitant and Ondansetron in the prevention of nausea and vomiting after TKA

开始日期2024-09-30

申办/合作机构

山东大学齐鲁医院

100 项与阿瑞匹坦相关的临床结果

登录后查看更多信息

100 项与阿瑞匹坦相关的转化医学

登录后查看更多信息

100 项与阿瑞匹坦相关的专利（医药）

登录后查看更多信息

1,227

项与阿瑞匹坦相关的文献（医药）

2025-01-01·NEUROPEPTIDES

NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model

Article

作者: Boada, M Danilo ; Gutierrez, Silvia

Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231^LUC+) with a modified murine cell line (E0771^LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771^LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771^LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.

2024-12-01·LIFE SCIENCES

Repurposing Aprepitant: Can it protect against doxorubicin-induced Chemobrain beyond its antiemetic role?

Article

作者: El-Mokadem, Bassant M ; El-Abhar, Hanan S. ; Gomaa, Asmaa A. ; Abdallah, Dalaal M ; Abdallah, Dalaal M. ; El-Mokadem, Bassant M. ; Gomaa, Asmaa A ; El-Abhar, Hanan S

The substance P (SP) and neurokinin-1 receptor (NK-1R) axis is crucial in numerous pathological processes, including inflammation, stress responses, pain perception, and vomiting. Consequently, aprepitant, an NK-1R blocker, is used as an antiemetic in chemotherapy, including the use of doxorubicin (DOX), but whether aprepitant can also assuage DOX-mediated chemobrain remains to be unveiled. Here, we scrutinized the potential neuroprotective effect and underlying mechanisms of aprepitant using DOX-induced chemobrain model, where rats were allocated into 4 groups (control, aprepitant, DOX, and DOX+ aprepitant). Cognitive deficits were assessed through behavioral tests and hippocampal structural alterations were determined by H&E and toluidine blue staining. Biochemical measurements were performed using ELISA, real-time quantitative PCR, western blotting, and immunohistochemical methods. Aprepitant improved cognitive responses, and hippocampal morphology, enhancing the presence of intact neurons. At the molecular tier, aprepitant significantly reduced hippocampal contents of SP and the inflammatory markers NF-κB and IL-1β. Additionally, it signified its antioxidant and antiapoptotic capacities by downregulating cleaved caspase-3 protein expression and curbing the content of malondialdehyde but boosted those of glutathione and Bcl-2. Aprepitant also downregulated the expression of miR-146a and turned off the endoplasmic reticulum (ER) stress cascade PERK/eIF-2α/ATF-4/CHOP. To recapitulate, aprepitant demonstrates a neuroprotective effect against DOX-mediated chemobrain by alleviating inflammatory, oxidative, and apoptotic responses, partly by reducing SP, ER stress, and miR-146a. These findings not only underscore the potential of aprepitant as a neuroprotective agent but also offer new understanding of the mechanisms behind chemobrain, leading to better therapeutic strategies for cancer patients.

2024-12-01·SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study

Article

作者: VanderWielen, Beth A ; Weingarten, Toby N ; VanderWielen, Beth A. ; Schroeder, Darrel R. ; Weingarten, Toby N. ; Schroeder, Darrel R ; Sprung, Juraj ; Storm, Andrew C. ; Storm, Andrew C

BACKGROUND:

Both the transoral gastric reduction (TORe) and endoscopic sleeve gastroplasty (ESG) procedures are novel endoscopic bariatric and metabolic therapies (EBMT). Our practice has an aggressive approach to prophylaxis of postoperative nausea and vomiting (PONV) for EBMT cases, but there is divergence of practice regarding use of prophylactic neurokinin-1 receptor (NK-1) antagonists (aprepitant, fosaprepitant). Herein, we determined the incidence of PONV and its potential association with NK-1 antagonist administration following EBMT.

METHODS:

We identified and reviewed medical records of patients who underwent EBMT between 2018 and 2023. Patients were divided into those administered or not administered an NK-1 antagonist. We analyzed rates of PONV, which was defined as rescue antiemetics during anesthesia recovery. A propensity score was calculated, and outcomes were assessed using generalized estimating equations with inverse probability of treatment weighting (IPTW).

RESULTS:

We identified 404 patients undergoing EBMT (256 [63%] TORe, 148 [37%] ESG), and of these 253 patients developed PONV, (62.6% [95% CI: 57.9% to 67.3%]). NK-1 antagonists were administered to 119 (29.5%) patients. PONV was experienced by 42 (35%) and 211 (74%) of patients who were or were not administered an NK-1 antagonist, respectively (IPTW OR = 0.18, [95%CI: 0.10 to 0.31], P < 0.001).

CONCLUSIONS:

EBMT has a high incidence of PONV during anesthesia recovery. Administration of a NK-1 antagonist as part of a multiagent PONV prophylaxis regimen dramatically reduces risk for this common adverse event.

147

项与阿瑞匹坦相关的新闻（医药）

2024-12-03

·PRNewswire

U.S. District Court Upholds Validity of CINVANTI® Patents

— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO, Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic product. The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI®. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI® until after the expiration of the patents in 2035. This decision is subject to appeal. "We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future," said Craig Collard, Chief Executive Officer of Heron. "The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs." About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权专利到期

2024-11-29

·齐鲁制药集团

用科技表达我们的爱｜齐鲁制药3款产品新增纳入2024年国家医保目录

11月28日，国家医保局公布2024年国家医保药品目录调整结果，有91种药品新增进入国家医保药品目录。新版目录内药品总数增至3159种，平均降价63%，预计2025年将为患者减负超500亿元。新版国家医保药品目录将于2025年1月1日在全国范围内正式实施。本次目录调整，齐鲁制药共有注射用罗普司亭N01、氯苯唑酸葡胺软胶囊、二甲双胍恩格列净片（Ⅵ）3款目录外产品成功纳入医保，目录内产品伊鲁阿克片成功扩大医保支付范围。目前，齐鲁制药累计纳入国家医保的产品已有208个。 1 首款国产注射用罗普司亭成功纳入医保目录在此次目录更新中，齐鲁制药研发生产的第二代长效血小板生成素受体激动剂（TPO-RA），也是首款获批上市的国产注射用罗普司亭——注射用罗普司亭N01（瑞立升®）成功纳入国家医保目录。注射用罗普司亭N01适用于对其他治疗（例如皮质类固醇、免疫球蛋白）反应不佳的成人（≥18周岁）慢性原发免疫性血小板减少症（ITP）患者。作为第二代长效TPO受体激动剂，罗普司亭具有起效快，有效率高，给药频率低，用药方便、安全等特点，弥补了现有治疗药物的不足。瑞立升®此次被纳入新版医保目录，将进一步提升国内血小板减少相关疾病的药物可及性，为ITP患者提供了新的治疗选择。 2 创新药伊鲁阿克片新增适应症进入医保本次目录调整在肿瘤等重大疾病治疗领域，纳入了多个具有重要临床价值的创新药物。齐鲁制药伊鲁阿克片（启欣可®）继纳入2023版国家医保目录后，本次又有新适应症纳入国家医保，扩大了医保支付范围，由仅限于“限既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者”调整为“限间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者”。这意味着伊鲁阿克全线覆盖ALK阳性局部晚期或转移性非小细胞肺癌患者，极大地减轻患者的经济负担。公司将进一步提升创新能力，快速推进创新药上市，并积极响应国家医药政策，不断提升药物的可及性，惠及更多患者。 3 罕见病药物纳入医保氯苯唑酸葡胺软胶囊惠及患者全球罕见病超过1万种，目前，只有不到5%的罕见病拥有针对性的治疗方案。本次调整新增的91种药品中，包含罕见病用药13个，齐鲁制药的氯苯唑酸葡胺软胶囊位列其中。齐鲁制药氯苯唑酸葡胺软胶囊为该产品国产首家获批上市，用于治疗成人转甲状腺素蛋白淀粉样变性多发性神经病（ATTR-PN）I期症状患者，可有效延缓周围神经功能损害。 ATTR-PN是一种罕见的遗传性、进行性加重、致死性疾病，30-40岁多发，且不可逆，严重危害患者生命。氯苯唑酸葡胺软胶囊原研产品于2020年在国内上市，治疗费用高昂。齐鲁制药勇于承担社会责任，积极探索解决罕见病患者用药的“最后一公里”障碍，在当年启动项目研发，于今年6月获得上市许可。氯苯唑酸葡胺软胶囊成功纳入医保，将大大降低ATTR-PN患者的经济负担，让更多罕见病患者得到更加规范的治疗。 4 累计208个产品进入国家医保目录持续助力健康中国建设在本次目录调整中，齐鲁制药二甲双胍恩格列净片（Ⅵ）也通过竞价进入医保，用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。在近几年的国家医保谈判中，齐鲁制药每年都有亮眼成绩：2022年，盐酸美金刚口溶膜等5个产品入选；2023年纳入伊鲁阿克片、孟鲁司特钠口溶膜、阿立哌唑口溶膜、阿瑞匹坦注射液等8个医保产品。目前，齐鲁制药已经有208个产品进入国家医保目录。齐鲁制药将继续秉持“大医精诚家国天下”的核心价值观，以解决目前未被满足的临床需求为导向，用“有温度的科技创新”，不断为健康中国建设添砖加瓦。撰稿：姜瑞丽、王颖、王亚楠、杨洪娟点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

上市批准申请上市

2024-11-19

·医药云端工作室

四川某三甲，将引进113个新品种，原研、仿制有要求（附名单、引进规则）

11月份是集采项目井喷的月份，也是新版医保目录公布的月份 11月26日，我们来聊聊相关话题 ↓↓↓↓↓↓ 文：子非鱼 11月19日，四川一家三甲医院---巴中市中心医院发出《关于接收2024年新药申报资料的公告》，该公告显示，根据临床诊疗工作的实际需求，医院将开始2024年新药遴选申报资料接收工作，共有113个药品纳入《巴中市中心医院待引进新药目录》。（以下下简称《目录》，目录附文后），要求于2024年11月19日至12月4日前申报，逾期不再受理。根据公开信息，巴中市中心医院始建于1943年，是一所集医疗、教学、科研、预防、保健、康养为一体的三级甲等综合医院，是巴中市医保定点医院，该院有南池院区、南坝院区、感染病院区三个院区，南池院区位于四川省巴中市巴州区南池河街1号，南坝院区及感染病院区位于四川省巴中市巴州区将军大道七支道。该院此次引进药品要求是在《目录》内的品种，且在四川省平台上挂网，此外，除外标注为急抢救药品、专科治疗用药或开展新技术新项目临床必需的药品，申报药品不能是四川省平台价格红区药品。根据《公告》显示，此次引进的药品只能是上述《目录》内的113个，包括102个化学药，11个中成药，《目录》对引进的部分品种做出了特殊要求，比如，阿瑞匹坦注射液（18ml∶130mg）有三个条件，分别对质量、转换比及包材做出要求：1.国产药品需要通过一致性评价；2.转换比为1；3.中硼硅玻璃管制注射剂瓶、注射液用局部覆聚四氟乙烯膜溴化丁基橡胶塞与抗生素瓶用铝塑组合盖包装。又比如，聚多卡醇注射液（2ml:20mg（1.0%））、盐酸普拉克索片等品种，“需要同时使用原研、进口药品及国产药品”；而对于屈螺酮炔雌醇片(Ⅱ)、雌二醇凝胶、地屈孕酮片、雌二醇片/雌二醇地屈孕酮片复合包装、甲氨蝶呤注射液、酒石酸唑吡坦片等品种，则均明确“需要原研、进口药品，无需国产药”。厂家申报需要按《新药申报资料目录及要求》办理，需要填报《2024年新药申报资料信息表》、质量保证、廉洁准入、新药申报承诺书、厂家委托等材料。此外，厂家必须从该院药品供应合同的配送公司中，按各个院区的合同关系，分别为该院南池院区、南坝院区、经开区院区指定配送公司，否则视为申报资料不合格，新药形式审查不予通过（集采中标药品除外）。 ps.这也为业界学习了解医院的配送商构成提供了一个真实的案例，从下表可以看出，四川省内医药商业的碎片化现状。图源：巴中市中心医院《关于接收2024年新药申报资料的公告》附件2 11月份是集采项目井喷的月份，也是新版医保目录公布的月份 11月26日，我们来聊聊相关话题 ↓↓↓↓↓↓ 四川引入新药的文章，可点击下方标题进入内容页：川大华西医院成办分院引入34个品种、停用1个公示（附名单）华西医院某下辖医院，引入45个药品，停用4个在院药品（附名单）华西医院终于进药了！61个品种，含5个中成药（附清单）中成药终于可以进华西医院了，但要国谈或1类新药...... 中成药及辅助用药，无一进入华西医院（附最新引进清单）华西医院否认拒绝中成药：不是一竿子打死，在用中药试剂就有100多种！

一致性评价

100 项与阿瑞匹坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02968	阿瑞匹坦	A04AD12	DB00673

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
术后恶心呕吐	欧盟	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	冰岛	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	列支敦士登	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	挪威	Merck Sharp & Dohme BV	2003-11-11
化疗引起的恶心和呕吐	美国	Merck & Co., Inc.	2003-03-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
生殖细胞和胚胎肿瘤	临床3期	美国	Merck Sharp & Dohme LLC	2007-12-01
乳腺癌	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
恶心	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
呕吐	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
重度抑郁症	临床3期	-	Merck Sharp & Dohme Corp.	2001-09-01
痤疮样疹	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
皮肤脂肪变性	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
甲沟炎	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
新型冠状病毒感染	临床2期	美国	Heron Therapeutics, Inc.	2020-07-20
晚期非小细胞肺癌	临床2期	中国	Merck Sharp & Dohme Corp.	2015-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2024	N/A	-	-	Fosaprepitant	簾夢餘願壓窪築鹽顧衊(遞壓築壓獵壓窪鹽糧鏇) = 壓獵衊遞齋窪積鹹憲窪醖齋鑰製鹹糧構憲獵築 (獵範獵蓋積鏇顧衊簾積 )	不佳	2024-05-24
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	窪膚顧鹹構選網窪艱網(餘夢糧襯艱鏇網築艱蓋) = 窪構廠膚鹹廠獵膚膚憲觸鹽顧餘網壓繭鏇餘觸 (簾網鬱壓積願襯鹹齋遞, 製選積膚夢顧選觸艱簾 ~ 獵構鹽獵艱窪糧顧遞齋) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	窪膚顧鹹構選網窪艱網(餘夢糧襯艱鏇網築艱蓋) = 廠衊獵製艱遞獵淵繭願觸鹽顧餘網壓繭鏇餘觸 (簾網鬱壓積願襯鹹齋遞, 製艱衊艱餘鏇憲鹹範鹽 ~ 窪襯獵繭積遞憲艱簾淵) 更多
NCT02939287 (CTgov)	临床3期	恶心 \| 呕吐	52	80 mg orally on Days 0 (Aprepitant)	繭獵艱廠鹽夢蓋艱廠壓(選糧齋齋鑰積鹽醖鏇鬱) = 夢願夢選窪膚鏇鏇壓築鹹鏇夢築衊糧襯網膚繭 (襯淵艱蓋範獵壓淵願鏇, 選繭膚鏇齋獵壓鹽膚糧 ~ 網餘築範範蓋廠膚築簾) 更多	-	2024-01-22
				+2 (Olanzapine)	繭獵艱廠鹽夢蓋艱廠壓(選糧齋齋鑰積鹽醖鏇鬱) = 構選簾鑰構構積夢積艱鹹鏇夢築衊糧襯網膚繭 (襯淵艱蓋範獵壓淵願鏇, 淵窪壓獵築鬱顧選醖淵 ~ 廠醖蓋網膚蓋顧範獵齋) 更多
NCT04873284 (Pubmed \| Transl Pediatr)	临床3期	化疗引起的恶心和呕吐	108	Intravenous fosaprepitant	艱網繭顧壓鑰網願窪遞(齋淵憲衊廠憲願選醖憲) = 廠壓鹹網積觸遞憲憲餘憲範窪壓齋願構構憲憲 (製糧簾製艱積選壓膚鹹 ) 更多	积极	2024-01-01
				Oral aprepitant	艱網繭顧壓鑰網願窪遞(齋淵憲衊廠憲願選醖憲) = 壓構艱遞獵膚廠膚鬱壓憲範窪壓齋願構構憲憲 (製糧簾製艱積選壓膚鹹 ) 更多
NCT03237611 (CTgov)	临床2期	化疗引起的恶心和呕吐	15	Ondansetron 16 MG+Aprepitant 125 mg+Dexamethasone+Fosaprepitant 115 MG	夢鑰選窪鬱鏇鑰選鹽鏇(糧餘齋鬱範構糧選願憲) = 範簾齋鏇夢獵顧艱糧構醖築艱艱壓淵醖鹹鹽鬱 (醖選襯遞築製簾鬱窪願, 鏇繭廠築餘夢窪構範獵 ~ 衊壓積鑰觸積築夢鹹艱) 更多	-	2023-11-13
ESMO2023 人工标引	临床2期	乳腺癌	76	Palonosetron+aprepitant+ olanzapine	憲夢網積遞餘製積淵鹹(範艱餘襯廠範繭鹹範廠) = 簾淵願觸構獵獵襯顧襯簾憲膚艱製衊觸齋壓蓋 (艱簾繭選網糧積鹹鏇壓, 9.4 ~ 27.5) 更多	不佳	2023-10-21
ESMO_ASIA2022	N/A	瘙痒 \| 肿瘤	36	Aprepitant	獵襯夢憲選窪糧選醖餘(願願願壓鹽廠齋網餘鏇) = 壓簾襯淵襯鹽窪衊夢糧範壓淵簾壓蓋鏇鏇顧築 (顧齋鹹齋淵鏇築顧簾齋 )	-	2022-12-03
NCT02646020 (Pubmed) 人工标引	临床2期	瘙痒	130	aprepitant	鏇範觸遞廠壓構製齋範(鑰艱淵鹽齋簾蓋簾鏇願) = 蓋糧壓網鬱襯鬱製齋糧齋醖膚鑰顧範糧觸壓觸 (觸鏇夢積鬱範網襯選鏇 ) 更多	积极	2022-10-05
				desloratadine	鏇範觸遞廠壓構製齋範(鑰艱淵鹽齋簾蓋簾鏇願) = 夢壓壓夢膚鹽夢鬱鏇襯齋醖膚鑰顧範糧觸壓觸 (觸鏇夢積鬱範網襯選鏇 ) 更多
NCT04470622 (CTgov)	临床2期	新型冠状病毒感染	27	Aprepitant (Treatment Group 1: Aprepitant Injectable Emulsion)	鬱選獵齋衊積齋糧鬱衊(襯願艱衊艱獵獵鹹艱獵) = 鏇鹽顧顧願積顧蓋襯淵網鏇糧夢構繭淵膚襯觸 (製蓋築糧鏇齋壓鏇膚獵, 繭襯膚製廠蓋鹽鏇構顧 ~ 齋醖製範築鹽廠鏇製構) 更多	-	2022-08-30
				Placebo (Treatment Group 2: Placebo)	鬱選獵齋衊積齋糧鬱衊(襯願艱衊艱獵獵鹹艱獵) = 鑰範繭壓餘鹹簾積壓廠網鏇糧夢構繭淵膚襯觸 (製蓋築糧鏇齋壓鏇膚獵, 鏇網積蓋糧鏇願鏇艱網 ~ 積衊簾鬱淵窪願衊餘憲) 更多
NCT02909478 (Pubmed)	临床3期	化疗引起的恶心和呕吐	320	Aprepitant plus palonosetron	(網憲夢醖衊醖衊簾衊選) = 繭鹹鹹醖積衊積遞襯築艱蓋壓鏇廠艱窪醖襯獵 (鹽簾鹽襯鹹餘鹽鑰糧鹹 )	积极	2022-07-01
				Dexamethasone plus palonosetron	(網憲夢醖衊醖衊簾衊選) = 鬱襯網淵廠鑰鹹願餘憲艱蓋壓鏇廠艱窪醖襯獵 (鹽簾鹽襯鹹餘鹽鑰糧鹹 )